New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:44 EDTPFE, MRK, INCY, AMGNMerck signs three clinical collaboration agreements to evaluate MK-3475
Merck (MRK) announced it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen (AMGN), Incyte (INCY) and Pfizer (PFE) to evaluate novel combination regimens with MK-3475, Merck's investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed.
News For MRK;AMGN;INCY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 27, 2015
17:13 EDTMRKMerck announces Januvia study achieved primary endpoint
Merck announced that the trial evaluating cardiovascular outcomes with Sitagliptin, or TECOS, of Merck's DPP-4 inhibitor, Januvia, or sitagliptin, achieved its primary endpoint of non-inferiority for the composite cardiovascular endpoint. Among secondary endpoints, there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo. The complete results of TECOS will be presented on June 8 at the Scientific Sessions of the American Diabetes Association. TECOS was an event-driven trial conducted in adults with type 2 diabetes and a history of cardiovascular disease. The study was designed to assess the CV safety of long-term treatment with Januvia as part of usual diabetes care compared with usual care without Januvia. The primary endpoint was the composite of time to the first of any of the following confirmed events: cardiovascular-related death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. TECOS enrolled 14,724 participants from 38 countries between December 2008 and July 2012. The median patient follow-up was approximately three years.
15:04 EDTMRK, PFENotable companies reporting before tomorrow's open
Subscribe for More Information
14:41 EDTPFEEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
13:43 EDTMRKEarnings Watch: Merck shares lower by about 5.6% since last earnings report
Subscribe for More Information
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
09:37 EDTMRKBarclays healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:41 EDTPFETelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
08:07 EDTAMGNBenefit of Amgen melanoma treatment questioned ahead of FDA meeting
In advisory committee documents ahead of a meeting scheduled for April 29 to discuss the biologics license application submitted by Amgen for talimogene laherparepvec for the treatment of injectable regionally or distantly metastatic melanoma, FDA staff wrote that "uncertainty regarding the clinical meaningfulness of the study 005/05 primary endpoint results, in the absence of a clear effect on overall survival, raises concern regarding both the existence and the magnitude of an overall benefit of talimogene laherparepvec." The PDUFA date for an FDA decision on approval is October 27. Reference Link
06:19 EDTMRK, PFEPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
07:58 EDTMRKMerck May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
05:35 EDTMRKMerck Phase 3 C-EDGE program shows high sustained virologic responses
Subscribe for More Information
April 23, 2015
16:39 EDTMRKACETO subsidiary to launch Timolol Maleate Ophthalmic Solution
Subscribe for More Information
05:40 EDTMRKMerck announces results from C-SURFER Phase 2/3 study
Subscribe for More Information
April 22, 2015
15:19 EDTAMGNAmgen management to meet with Piper Jaffray
Group luncheon to be held in Boston on April 27 hosted by Piper Jaffray.
09:22 EDTAMGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
08:18 EDTMRKOrganovo enters into a collaboration agreement with Merck Sharp and Dohme
Subscribe for More Information
07:59 EDTAMGNAmgen price target raised to $189 from $164 at Cowen
Subscribe for More Information
07:29 EDTAMGNAmgen estimates and price target raised at UBS
Subscribe for More Information
06:03 EDTAMGNAmgen price target raised to $192 from $187 at Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use